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vaccine prevents 408 469 cases of precancerous cervical lesions. Due to HPV vacci-
nation the incidence of CC is reduced by1858 cases, which corresponds to 31 588
years of life saved in the vaccinated cohort. The cost of an additional life-year saved
is 10,166 € (405,535 rubles), and the cost of averted CIN case is 786 € (31,360 rubles).
CONCLUSIONS: Vaccination with Human Papillomavirus recombinant vaccine
seems a cost-effective option in Russia.
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OBJECTIVES: Pertussis incidence has been increasing in adolescents and adults in
the last two decades with transmission to vulnerable young infants. This epidemi-
ological changing has raised interest in the cost-effectiveness of booster vaccina-
tion (extra administration of a vaccine after an earlier dose). A critical review of
economic evaluations of pertussis booster vaccination was performed in order to
develop recommendations for future studies. This review illustrates specific chal-
lenges encountered in economic evaluations of vaccination programmes.
METHODS: The literature search covered cost-effectiveness studies of pertussis
booster vaccination, published until November 2010, worldwide. We extracted in-
formation on model structures, input data and results. RESULTS: We identified 13
publications (9 distinct models) referring to cost-effectiveness of pertussis booster
vaccination. The most frequently studied strategies were adolescent booster vac-
cination (9/13), cocooning strategy, i.e. vaccination of mothers and family mem-
ber(s) of newborn infants (6/13), one-time adult pertussis booster vaccination (6/
13), and decennial vaccination of adults with pertussis containing boosters (4/13).
All studies found that booster vaccination was a cost-effective or cost-saving strat-
egy compared to no booster vaccination. However, conclusions differed concerning
the exact age groups to vaccinate and frequency of vaccination. Results were
strongly affected by assumptions regarding unreported cases and uncertainty
around incidence. Four models ignored herd immunity (HI) effects, 3 assumed
incidence reduction attributable to HI, and 2 were transmission dynamic models
predicting HI effects. Several studies considered incidence at steady state, al-
though it was not reached before 80 years for some strategies. Methods used to
compare multiple strategies were often inappropriate. CONCLUSIONS: Reviewed
studies showed that pertussis booster vaccination is cost-effective or dominant vs.
no booster vaccination, but did not identify any optimal vaccination schedule.
Results are variable due to uncertainty surrounding disease incidence and extent
of HI. Future economic evaluations should explore a wider range of strategies,
according to local context.
PIN70
MODELLING THE EPIDEMIOLOGICAL IMPACT OF ROTAVIRUS VACCINATION TO
ASSESS ITS COST-EFFECTIVENESS IN ENGLAND AND WALES
Atkins KE1, Shim E2, Carroll S3, Quilici S4, Galvani AP1
1Yale University, New Haven, CT, USA, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Sanofi
Pasteur MSD, Maidenhead, UK, 4Sanofi Pasteur MSD, Lyon, France
OBJECTIVES: Rotavirus infection causes severe gastroenteritis in children world-
wide. Its disease burden has been reduced in countries where mass rotavirus vac-
cination programmes have been introduced. England and Wales (E&W) have not
yet implemented such a mass vaccination programme, but are currently re-evalu-
ating its potential cost-effectiveness. Our study uses a dynamic model to predict
the epidemiological and economical effect of such a mass vaccination programme
in E&W beginning in the autumn of 2011. METHODS: A previously published age-
structured dynamic model was upgraded and parameterised with country-specific
data for the introduction of the oral rotavirus pentavalent vaccine. We report the
impact of vaccination on disease incidence reduction, timing of seasonal epidem-
ics and herd immunity levels. The model was then used to assess whether a mass
vaccination of RotaTeq is cost-effective and affordable for E&W. RESULTS: Our
results predict that vaccination can reduce the burden of severe disease by 70% and
delay the epidemic peak by two and a half months with coverage of 95%. Our
calculations further show that herd immunity accounts for about a quarter of the
reduction in incidence. If the pentavalent vaccine-induced immunity does not
wane over five years, severe disease in children under five years of age is elimi-
nated within two years after the introduction of vaccination. The probability of a
mass vaccination strategy being cost-effective is presented under likely vaccine
waning scenarios, administration cost assumptions and possible dose prices.
CONCLUSIONS: This work allows policymakers to determine both the epidemio-
logical impact and cost implications of a mass vaccination programme against
rotavirus with the pentavalent vaccine in England and Wales. Although long con-
sidered unlikely to be cost-effective in E&W using static models, the pentavalent
vaccine demonstrates a significant impact in reducing rotavirus cases at accept-
able levels of cost-effectiveness when using appropriate modelling techniques.
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OBJECTIVES: Evaluation of comparative cost-effectiveness of CAP treatment with
moxifloxacin versus combined therapy with cefotaxime and macrolides in adult
patients.METHODS: Patients were randomized in two groups. MOX group received
moxifloxacin 400 mg i.v. once-daily with further switch to oral formulation 400 mg
daily. COMB group received either cefotaxime 1000 mg i.m. 3 times per day as
monotherapy or in combination with oral azithromycin or clarithromycin. Efficacy
and safety criteria were evaluated according to clinical data, laboratory tests and
X-ray examination. Cost-effectiveness analysis was performed. RESULTS: MOX
group included 30 patients, mean age 33.616.5 years; COMB group included 50
patients, mean age 26.515.6 years. The efficacy of moxifloxacin treatment was
96.7%, in-hospital stay duration was 15.93.3 days. The efficacy of treatment in
COMB group was 88.0%, patients were discharged after 18.23.7 days. Direct med-
ical costs including antibacterial treatment and in-hospital days were 46712 RUB
(€1173) in MOX group and 46970 RUB (€1180) in COMB group. CERMOX 48307 RUB
(€1213), CERCOMB 53375 RUB (€1340). CONCLUSIONS: CAP treatment with moxi-
floxacin compared to combined therapy with cefotaxime and macrolides in adult
patients is more effective and cost saving technology.
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OBJECTIVES:To assess the cost-effectiveness of universal rotavirus immunization,
explicitly the use of Rotateq® and affordability of implementing rotavirus immu-
nization based on the Global Alliance for Vaccines and Immunization (GAVI)-sub-
sidized vaccine price in the context of Vietnamese health care system for the next
5 years. METHODS: An age-structured cohort model was developed for the 2009
Vietnamese birth cohort and applied a 5-year time horizon with time cycle of 1
month for 1-year-old children and annually thereafter. Results from no vaccina-
tion and vaccination were compared. Outcomes included rotavirus episodes re-
quiring home-treatment, outpatient visits, hospitalizations and deaths. Multiple
outcomes per rotavirus infection are possible in the model. Acceptability and af-
fordability analyses were done using Monte Carlo simulations. Costs were ex-
pressed in 2009 US$. RESULTS: Rotavirus immunization would not completely
protect under-five-year-old children against rotavirus infection due to partial na-
ture of vaccine immunity, however, would effectively reduce rotavirus severe cases
by 55%. Under the GAVI-subsidized price, the minimum vaccination budget
would be US$1.6 million annually. In the base-case, the incremental cost per qual-
ity-adjusted-life-year (QALY) was US$665 from health care perspective,Vietnam-
ese per-capita-GDP in 2009. Affordability results showed that at the GAVI-subsi-
dized vaccine price, rotavirus vaccination could be affordable in Vietnam.
CONCLUSIONS: Rotavirus immunization in Vietnam would be a cost-effective
health intervention. However, it only becomes affordable under the GAVI’s finan-
cial support. Vaccine price is the most crucial factor to decision-makers regarding
introducing this vaccine into the country’s immunization. Given the high under-
five mortality rate, results showed that rotavirus immunization is the “best hope”
for prevention of rotavirus-related diarrhoeal disease in Vietnam. In the next five
years, Vietnam is definitely in debt to external financial support in implementing
rotavirus vaccination. It is recommended that new and cheaper rotavirus vaccine
candidates be developed to speed up rotavirus vaccines introduction in the devel-
oping world.
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OBJECTIVES: To estimate the cost and effects of initiating treatment with atazana-
vir/r (ATV/r) compared to darunavir/r (DRV/r), lopinavir/r (LPV/r) and efavirenz
(EFV) in treatment-naïve HIV-1 patients in Italy(I), Spain(S), Portugal(P) and UK.
METHODS: HIV-disease progression is modeled using a micro-simulation model.
Health states are a function of HIV-RNA, CD4cells, AIDS defining events (ADEs),
and comorbidities. At model entry patients receive either ATV/r, LPV/r, DRV/r, or
EFV with a treatment backbone. Treatment-sequences are modelled following
treatment discontinuation due to virological failure, adverse events, resistance, or
treatment related co-morbidities. Country-specific patterns for HIV related drug
use were applied to estimate specific treatment sequences; maximized at 8 treat-
ment lines after which patient were assumed to be untreated. Efficacy and tolera-
bility inputs of first line treatments were derived from a Mixed-Treatment-Com-
parison, supplemented by published literature and product-SPCs for remaining
drug specific data for efficacy, tolerability and safety. Occurrence of (non)-AIDS
defining malignancies was linked to current CD4cell count and independent of
therapy. Cost estimates were based on country specific sources. A 25-year time-
horizon was chosen for the base-case analyses. A payer’s perspective was chosen
and country-specific discount rates were applied. RESULTS:Across countries, total
costs per patient who started with ATV/r ranged between €126,947(I) and
€154,285(P). Predicted incremental costs of ATV/r versus comparators ranged be-
tween -€27,004 (S) versus LPV/r and -€13,165 (P) versus EFV. Estimated incremental
QALYs of ATV/r versus comparators varied from -0.68(UK) versus EFV to 0.78(UK)
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versus DRV/r. CONCLUSIONS: The value of initiation with ATV/r in terms of dura-
ble viral suppression and favourable side-effect profile was most prominent in
Spain. In general, starting with ATV/r is suggested to be a cost-effective treatment
strategy for HIV-1 treatment-naïve patients in most of the country-specific com-
parisons made.
PIN74
A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH 23-
VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN GERMANY
Jiang Y1, Gauthier A1, Annemans L2, van der Linden M3, Nicolas-Spony L4, Bresse X4
1Amaris Consulting UK, London, UK, 2Ghent University, Ghent, Belgium, 3National Reference
Centre for Streptococci, Aachen, Germany, 4Sanofi Pasteur MSD, Lyon, France
OBJECTIVES: Streptococcus pneumoniae is a leading cause of life-threatening pneu-
mococcal diseases (PDs). In Germany, PPV23 has been recommended in the elderly
(aged 60 and over) since 1998. In 2006, the pneumococcal conjugate vaccine (PCV)
was introduced in children. The US experience showed that PCV vaccination of
children led, ten years after its introduction, to a decrease in IPD incidence caused
by the PCV serotypes not only in vaccinated children but also in unvaccinated
adults. This study aimed to re-assess the good cost-effectiveness profile of PPV23
vs. no vaccination (NoVac) in the elderly in Germany, accounting for epidemiolog-
ical changes in adults due to PCV vaccination of children.METHODS:A population-
based Markov model was developed, consisting of five health states: no PD, IPD
(invasive PD), NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis
sequelae (PMS) and death. A cohort of individuals was followed until death assum-
ing vaccination or no vaccination. IPD and NBPP incidence were retrieved from
German sources, while the changes in IPD incidence were estimated based on US
data. IPD and NBPP case-fatality rates, probability of developing PMS, vaccine ef-
fectiveness, vaccine waning function and utilities were retrieved from the pub-
lished literature. A discount rate of 3% was applied to costs and effects. RESULTS:
PPV23 was associated with a discounted increment of 1,587 QALYs. From the third
party payer’s (TPP) perspective, incremental costs were estimated at €28 million
and the ICER was €17,700/QALY gained. From the societal perspective, PPV23 was
associated with an increment of €14 million, and the ICER was €8579/QALY gained.
Results were sensitive to vaccine effectiveness and epidemiological trends
assumptions. CONCLUSIONS: The model suggests that vaccinating the elderly
with PPV23 is cost-effective in Germany. As PPV23 covers 80%-90% of all serotypes
causing IPD, it is still cost-effective despite the reduction in IPD incidence in adults
due to PCV vaccination of children.
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Vaccination of elderly (65 and older) population against Streptococcus pneumonia
is recommended in Poland but not publicly funded. Therefore coverage rates for
pneumococcal vaccine have remained very low (less than 1%) meaning that no
benefit of the vaccine has been felt in Poland and individuals remain largely
unprotected. OBJECTIVES: An analysis was designed to analyse the cost-effective-
ness of implementing a public vaccination programme in the elderly considering a
50% reimbursement of a 23-valent polysaccharide vaccine (PPV23) by the public
health care payer: Narodowy Fundusz Zdrowia (NFZ). METHODS: To do so, a semi-
dynamic Markov model with a 1-year cycle length was developed, allowing up to 10
cohorts to enter the model over the lifetime horizon. The model was populated
with demographic, epidemiological and cost data from Polish sources or when
unavailable, from international literature. The analysis included routine vaccina-
tion of all elderly or high-risk (HR) elderly versus no vaccination. Deterministic and
probabilistic sensitivity analyses (DSA and PSA, respectively) were conducted to
assess the robustness of the cost-effectiveness results. RESULTS: The vaccination
program targeting all elderly in Poland would avoid 8935 pneumococcal infections,
2542 hospitalisations, 671 deaths; for HR elderly the program would avoid 5886
infections, 1673 hospitalisations and 441 deaths. The incremental cost per QALY
gained for vaccination in all elderly was PLN 3382 and was PLN 2148 for HR elderly.
Ratios were even lower when actual in and outpatients’ costs instead of reim-
bursed costs were considered. Finally, ratios estimated in the base case and the
sensitivity analyses, were well below the gross domestic product (GDP) per capita
(i.e. PLN 37,055). CONCLUSIONS: This analysis suggests that vaccinating all elderly
regardless of risk status with a 23-valent pneumococcal vaccine is highly cost-
effective and supports the continued recommendation of pneumococcal vaccines,
as well as their public funding in Poland.
PIN76
COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13)
AND 23-VALENT (PPV23) PNEUMOCOCCAL VACCINES FOR SENIOR ADULTS IN
BRAZIL
Fujii RK1, Mould JF2, Presa J3, Jardim E3, Sato R4, Strutton DR5
1Pfizer Pharmaceutics inc., São Paulo, São Paulo, Brazil, 2Pfizer, Inc., New York, NY, USA, 3Pfizer
Parmaceutics Inc., São Paulo, São Paulo, Brazil, 4Pfizer, New York, NY, USA, 5Pfizer, Inc.,
Collegeville, PA, USA
OBJECTIVES: According to World Health Organization, pneumococcal related dis-
eases is a major public health concern in the world, especially for those under 2
years of age and older adults. The objective of this analysis is to evaluate the cost
effectiveness of vaccinating the Brazilian population 65 years of age and older with
the 13-valent pneumococcal conjugate vaccine (PCV 13) in comparison to the 23-
valent pneumococcal polysaccharide vaccine (PPV 23), each as a single dose, from
the public payer perspective. METHODS: In order to estimate the costs and the
impact of the pneumococcal disease over a 35-year time horizon period, including
invasive pneumococcal disease, hospitalized pneumonia and non complicated
pneumonia, a patient level microsimulation model simulating vaccination and
outcomes of one cohort of 12,653,613 individuals over 65 years of age was adapted
to the Brazilian public health care system. The probabilities and direct medical
costs were extracted from literature review and DATASUS for January 2011, with
costs presented in US$ 2010. The effectiveness measures were expressed as cases
of pneumococcal diseases avoided, overall deaths avoided, and life years (LYs)
saved. Probabilistic sensitivity analyses were conducted considering key variables.
A discount rate of 5% was applied. RESULTS: Vaccinating with PCV13 prevents 349
additional cases of acute meningitis, 1,589 cases of invasive pneumococcal disease,
100,158 hospitalized pneumonia, 12,954 non complicated pneumonia and 30,904
deaths, saving 139,189,74 LYs compared to PPV23 over 35 years. The total costs
including vaccination costs and medical costs resulted in US$135,625,000 less for
PCV13 compared to PCV23 (US$5,875,625,000 vs. US$5,740,000,000). The model
showed robustness through sensitivity analyses.CONCLUSIONS:The analysis sug-
gests that vaccinating adults with PCV13 in Brazil is cost-saving compared to
PPV23. The results in economic and disease burden are substantial and they sup-
port the decision making in favor of PCV13 for its high impact in public health.
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OBJECTIVES: Systemic Candida infections (SCI) occur predominantly in intensive
care unit (ICU) patients and are a common cause of morbidity and mortality. The
increasing prevalence of SCI caused by Candida non-albicans species and higher
resistance to fluconazole and azoles in general have prompted changes in the
management of SCI. Current guidelines tend to favour treatment initiation with a
broad spectrum antifungal such as an echinocandin with subsequent switch to
fluconazole if isolates are sensitive (de-escalation) over the traditional first-line
treatment with fluconazole (escalation). Cost-effectiveness of de-escalation strat-
egy versus escalation in patients with SCI was evaluated from the UK NHS
perspective. METHODS: Cost-effectiveness was estimated using decision analysis
based on clinical and microbiological data from pertinent studies. The model ho-
rizon was 42 days, and was extrapolated to cover a life time horizon. RESULTS: In
patients with fluconazole-resistant isolates, de-escalation avoids 30% more deaths
and successfully treats 23% more patients than escalation, with cost savings of
£1621 per treated patient. In the overall population with SCI, initial treatment with
micafungin results in 1.2% fewer deaths at a marginal cost of £740 per patient alive.
Over a lifetime horizon, the incremental cost effectiveness of de-escalation com-
pared with escalation is £15,522 per life-year and £25,673 per QALY. Univariate
analyses indicate that the incremental costs per QALY of de-escalation are highly
sensitive to the fluconazole-susceptibility profile, late mortality in fluconazole-
resistant infections, fluconazole clinical success rate, excess hospitalization, life
expectancy, underlying diseases and follow-up costs. CONCLUSIONS: The de-es-
calation strategy is associated with better clinical outcomes and improved survival,
particularly among patients with fluconazole-resistant Candida strains. De-esca-
lation from initial treatment with micafungin is a cost effective alternative to tra-
ditional escalation approach from a UK NHS perspective with a differential cost per
QALY below the recognised willingness to pay threshold of £30,000.
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OBJECTIVES: Respiratory syncytial virus (RSV) infection is one of the major causes
of respiratory symptoms in infants in many countries, infecting virtually every
child by the age of two. Currently, several Phase 1 trials with RSV vaccines in
infants are running or have been completed. Although no efficacy estimates are yet
available, cost-effectiveness estimates might be informative enabling preliminary
positioning. METHODS: A decision analysis model was developed following a
Dutch birth cohort for 12 months. Vaccination strategies that were reviewed in-
cluded vaccination at specific ages, different dosing schemes and seasonal versus
year round vaccination. The impact of the assumptions was explored in sensitivity
analyses. Outcome measures included number of GP visits, hospitalizations and
deaths, costs, quality-adjusted life years and ICERs. RESULTS: Without vaccina-
tion, an annual number of 28,738 of RSV-related GP visits, 1,623 hospitalizations,
and 4.5 deaths are estimated in the 0-1 year olds. The total cost to society in the
non-vaccination scenario was €7.7 million and the annual disease burden was
estimated at 597 QALYs. In case all infants would be offered a 3-dose RSV vaccina-
tion scheme at 0/1/3 months of age, the total annual net costs were estimated to
increase to €21.2 million but a significant number of hospitalizations and deaths
could be averted, 544 and 1.5 respectively. The ICER was estimated € 34,142 (95%CI:
€ 21,652 - € 87,766) per QALY. A reduced dose schedule, seasonal vaccination, out-of
pocket payments all resulted in a more favorable ICERs while lowering the ex-
pected vaccine efficacy or delaying the time of vaccination in less favorable ICERs.
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